Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.

Uy, Geoffrey L; Newell, Laura F; Lin, Tara L; Goldberg, Stuart L; Wieduwilt, Matthew J; Ryan, Robert J; Faderl, Stefan; Lancet, Jeffrey E

Uy, Geoffrey L; Newell, Laura F; Lin, Tara L; Goldberg, Stuart L; Wieduwilt, Matthew J; Ryan, Robert J; Faderl, Stefan; Lancet, Jeffrey E.

Affiliation

Uy GL; Division of Oncology, Washington University School of Medicine, St. Louis, MO.
Newell LF; Knight Cancer Institute, Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR.
Lin TL; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.
Goldberg SL; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
Wieduwilt MJ; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK.
Ryan RJ; Department of Biostatistics, Jazz Pharmaceuticals, Philadelphia, PA.
Faderl S; Department of Clinical Development, Jazz Pharmaceuticals, Palo Alto, CA; and.
Lancet JE; Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

Blood Adv ; 6(17): 4989-4993, 2022 09 13.

Article de En | MEDLINE | ID: mdl-35443022

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Daunorubicine / Seconde tumeur primitive / Cytarabine Type d'étude: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limites: Aged / Humans Langue: En Journal: Blood Adv Année: 2022 Type de document: Article Pays d'affiliation: Macao

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google